Paclitaxel
FDA approves smaller paclitaxel-coated balloon for PAD
The FDA approved a paclitaxel-coated balloon catheter to treat peripheral artery disease in the superficial femoral and popliteal arteries that is compatible with 0.018" guidewires, Medtronic announced.
SAFE PAD: Paclitaxel-coated devices noninferior to uncoated devices for mortality
ATLANTA — An analysis of 160,000 Medicare beneficiaries demonstrated the noninferiority of paclitaxel-coated devices for mortality compared with uncoated devices for the treatment of peripheral artery disease, a speaker reported.
Paclitaxel-coated balloon does not confer elevated mortality risk at 5 years
In a patient-level meta-analysis of two pivotal trials of a paclitaxel-coated balloon, the paclitaxel-coated balloon was not associated with elevated risk for mortality in patients with peripheral artery disease at 5 years.
Speaker: Time to ‘move on’ from mortality-related concerns of paclitaxel-coated devices
Contemporary data suggest paclitaxel-coated devices do not elevate mortality risk in patients with peripheral artery disease, and they should be used more routinely, according to a speaker.
Oral paclitaxel plus encequidar shows superior tumor response in metastatic breast cancer
VIDEO: OUTBACK trial shows no benefit of adjuvant chemotherapy in locally advanced cervical cancer
In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.
VIDEO: Some breast cancer patients may be treated without chemotherapy
In this video, Daphna Yael Spiegel, MD, an instructor in radiation oncology at Beth Israel Deaconess Medical Center, spoke with Healio about data from the WSG-ADAPT HER2+/HR– trial presented at ASCO 2021.
De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype
A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer.
In FDA-designed cohort study, mortality risk not related to paclitaxel-coated devices
In the SAFE-PAD cohort study of patients with peripheral artery disease designed in part by the FDA, there was no difference in mortality between those treated with paclitaxel-coated devices and those treated with uncoated devices.
Low-dose paclitaxel-coated balloon noninferior to higher-dose PCB for treatment of PAD
In a head-to-head trial, a low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon for treatment of patients with peripheral artery disease.